Irinotecan Kabi (Irinotecan Hydrochloride Trihydrate)

Irinotecan Kabi is a Topoisomerase I inhibitor used in oncology to target DNA replication in malignant cells.

• Metastatic colorectal cancer: improves overall survival and tumor response when used in combination chemotherapy regimens.
• Other solid tumors: provides antitumor activity in selected solid tumor types such as gastric and pancreatic cancers.
• Combination therapy: enhances efficacy of fluoropyrimidine‑based regimens in advanced colorectal cancer.

• Irinotecan is converted intracellularly to its active metabolite SN‑38, which binds to the DNA‑topoisomerase I complex. This stabilizes the transient single‑strand breaks introduced during DNA replication, preventing relegation and leading to accumulation of DNA damage. The resulting inhibition of DNA synthesis and transcription triggers apoptosis in rapidly dividing tumor cells. The effect is cell‑cycle dependent, predominantly affecting cells in S‑phase, and contributes to tumor shrinkage observed clinically.

Irinotecan Kabi may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects

• Nausea: mild to moderate nausea often occurring during or after infusion.
• Diarrhea: acute onset watery diarrhea that may require antidiarrheal therapy.
• Fatigue: generalized tiredness affecting daily activities.
• Neutropenia: reduced neutrophil count increasing infection risk.

Serious or Rare Side Effects

• Severe neutropenia: profound drop in white blood cells leading to febrile neutropenia.
• Febrile neutropenia: fever accompanying low neutrophil levels, requiring urgent medical attention.
• Severe diarrhea (colitis): may progress to dehydration and electrolyte imbalance.
• Allergic reactions: anaphylaxis or severe hypersensitivity requiring immediate treatment.

Prior to using Irinotecan Kabi, clinicians should consider several safety measures.

• Assess baseline blood counts: obtain a complete blood count to evaluate neutrophil and platelet levels.
• Monitor liver function: evaluate hepatic enzymes as irinotecan metabolism is hepatic.
• Adjust dose in hepatic impairment: consider dose reduction for patients with elevated bilirubin.
• Avoid concurrent strong CYP3A4 inhibitors: these can increase SN‑38 exposure and toxicity.
• Educate patients on diarrhea management: provide instructions for early use of antidiarrheal agents.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Irinotecan Kabi interacts with several drugs that can modify its efficacy or safety.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole, ritonavir): may raise SN‑38 levels and increase toxicity.
• UGT1A1 inhibitors (e.g., atazanavir): can reduce SN‑38 clearance, heightening risk of neutropenia and diarrhea.

Moderate Interactions (Monitor Closely)

• CYP3A4 inducers (e.g., rifampin, phenytoin): may lower irinotecan exposure, reducing therapeutic effect.
• Anticoagulants (e.g., warfarin): increased bleeding risk due to mucosal damage from diarrhea.
• Other myelosuppressive agents: additive bone marrow suppression requiring close blood count monitoring.